WASHINGTON--(EON: Enhanced Online News)--The Biotechnology Innovation Organization (BIO) today announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to discover trends in life sciences, network with peers and potential partners and explore investment opportunities. Established and emerging publicly traded and select private biotech companies are the focus of the event.
“The best way to find investment opportunities is through education, networking and one-on-one partnering—all of which happens at BIO’s CEO & Investor Conference. We offer an event designed to propel partnerships that lead to medical breakthroughs never imagined possible”
“The best way to find investment opportunities is through education, networking and one-on-one partnering—all of which happens at BIO’s CEO & Investor Conference. We offer an event designed to propel partnerships that lead to medical breakthroughs never imagined possible,” said BIO President and CEO Jim Greenwood. “This annual conference attracts industry analysts, investment bankers and senior biotechnology executives - all in search of opportunities that will help them accomplish their objectives. We have lined up fireside chats hosted by industry leaders, company presentations from innovative firms, panel discussions on industry trends and individual partnering meetings between biopharma executives and investors. This event again offers enormous opportunities for companies and investors to build new and productive partnerships.”
Two industry leaders are slated for Fireside Chats and more will be announced in the near future. Those scheduled include:
- Dr. Giovanni Caforio, Chief Executive Officer (CEO) of Bristol-Myers Squibb. Caforio has been with the company since 2000, assuming the role of CEO in May, 2015. He has a long history of leadership positions in the biotech industry.
- Dr. Tony Coles, CEO of Yumanity Therapeutics. Coles is a founding investor in the company and also serves as chairman and chief executive officer of TRATE Enterprises, LLC. In addition to holding leadership positions within oncology, internal medicine and cardiology sectors, Coles was named to the NIH working group tasked with charting the course for President Obama’s Precision Medicine Initiative.
More than 175 company presentations by senior-level executives are expected this year – each designed to showcase their respective product pipelines, R&D activities, and investment goals before an audience of investors, research analysts, investment bankers and industry executives. Educational panel discussions around both therapeutics and business topics are also planned.
Discounted rates for early registration will end 5:00 PM EST today.
Advance media registration is available for qualified reporters working full time for print, broadcast and web publications with valid press credentials.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
CEO & Investor Conference
February 13-14, 2017
Asia International Conference
March 14-15, 2017
March 20-22, 2017